{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T07:17:03Z","timestamp":1790752623807,"version":"4.1.0"},"reference-count":54,"publisher":"EDP Sciences","issue":"6-7","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Med Sci (Paris)"],"published-print":{"date-parts":[[2010,6]]},"DOI":"10.1051\/medsci\/2010266-7627","type":"journal-article","created":{"date-parts":[[2011,3,1]],"date-time":"2011-03-01T14:32:25Z","timestamp":1298989945000},"page":"627-635","source":"Crossref","is-referenced-by-count":12,"title":["Chaperons pharmacologiques"],"prefix":"10.1051","volume":"26","author":[{"given":"Christiane","family":"Mendre","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bernard","family":"Mouillac","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"250","published-online":{"date-parts":[[2010,6,15]]},"reference":[{"key":"R1","doi-asserted-by":"crossref","unstructured":"Ellgaard L, Helenius A. Quality control in the endoplasmic reticulum.Nature Rev Mol Cell Biol2003 ; 4 : 181-91.","DOI":"10.1038\/nrm1052"},{"key":"R2","doi-asserted-by":"crossref","unstructured":"Anelli T, Sitia R. Protein quality control in the early secretory pathway.EMBOJ2008 ; 27 : 315-27.","DOI":"10.1038\/sj.emboj.7601974"},{"key":"R3","doi-asserted-by":"crossref","unstructured":"Arrigo AP. Chaperons mol\u00e9culaires et repliement des prot\u00e9ines.MedSci (Paris)2005 ; 21 : 619-25.","DOI":"10.1051\/medsci\/2005216-7619"},{"key":"R4","doi-asserted-by":"crossref","unstructured":"Tsai B, Ye Y, Rapoport TA. Retro-translocation of proteins from the endoplasmic reticulum into the cytosol.Nature Rev Mol Cell Biol2002 ; 3 : 246-55.","DOI":"10.1038\/nrm780"},{"key":"R5","doi-asserted-by":"crossref","unstructured":"Cohen FE, Kelly JW. Therapeutic approaches to protein-misfolfding diseases.Nature2003 ; 426 : 905-9.","DOI":"10.1038\/nature02265"},{"key":"R6","doi-asserted-by":"crossref","unstructured":"Chaudhuri TK, Paul S. Protein-misfolding diseases and chaperone-based therapeutic approaches.FEBSJ2006 ; 273 : 1331-49.","DOI":"10.1111\/j.1742-4658.2006.05181.x"},{"key":"R7","doi-asserted-by":"crossref","unstructured":"Conn PM, Ulloa-Aguirre A, Ito J, Janovick JA. G protein-coupled receptors trafficking in health and disease : lessons learned to prepare for therapeutic mutant rescuein vivo. Pharmacol Rev2007 ; 59 : 225-50.","DOI":"10.1124\/pr.59.3.2"},{"key":"R8","doi-asserted-by":"crossref","unstructured":"Sato S, Ward CL, Krouse ME,et al. Glycerol reverses the misfolding phenotype of the most common cystic fibrosis mutation.J Biol Chem1996 ; 271 : 635-8.","DOI":"10.1074\/jbc.271.2.635"},{"key":"R9","doi-asserted-by":"crossref","unstructured":"Oueslati M, Hermosilla R, Sch\u00f6nenberger E,et al. Rescue of a nephrogenic diabetes insipiduscausing vasopressin V2 receptor mutant by cell-penetrating peptides. JBiol Chem2007 ; 282 : 20676-85.","DOI":"10.1074\/jbc.M611530200"},{"key":"R10","doi-asserted-by":"crossref","unstructured":"Loo TW, Clarke DM. Correction of defective protein kinesis of human P-glycoprotein mutants by substrates and modulators.J Biol Chem1997 ; 272 : 709-12.","DOI":"10.1074\/jbc.272.2.709"},{"key":"R11","doi-asserted-by":"crossref","unstructured":"Morello JP, Salahpour A, Laperri\u00e8re A,et al. Pharmacological chaperones rescue cell-surface expression and function of misfolded V2 vasopressin receptor mutants.J Clin Invest2000 ; 105 : 887-95.","DOI":"10.1172\/JCI8688"},{"key":"R12","doi-asserted-by":"crossref","unstructured":"Bernier V, Morello JP, Zarruk A,et al. Pharmacologic chaperones as a potential treatment for Xlinked nephrogenic diabetes insipidus.J Am Soc Nephrol2006 ; 17 : 232-43.","DOI":"10.1681\/ASN.2005080854"},{"key":"R13","doi-asserted-by":"crossref","unstructured":"Jean-Alphonse F, Perkovska S, Frantz MC,et al. Biased agonist pharmacochaperones of the AVP V2 receptor may treat congenital nephrogenic diabetes insipidus.J Am Soc Nephrol2009 ; 20 : 2190-203.","DOI":"10.1681\/ASN.2008121289"},{"key":"R14","doi-asserted-by":"crossref","unstructured":"Robben JH, Sze M, Knoers NV, Deen PM. Functional rescue of vasopressin V2 receptor mutants in MDCK cells by pharmacochaperones: relevance to therapy of nephrogenic diabetes insipidus.Am J Physiol Renal Physiol2007 ; 292 : F253-60.","DOI":"10.1152\/ajprenal.00247.2006"},{"key":"R15","doi-asserted-by":"crossref","unstructured":"Conn PM, Janovick JA. Drug development and the cellular quality control system.Trends Pharmacol Sci2009 ; 30 : 228-33.","DOI":"10.1016\/j.tips.2009.02.002"},{"key":"R16","doi-asserted-by":"crossref","unstructured":"Li T, Sandberg MA, Pawlyk BS,et al. Effect of vitamine A supplementation on rhodopsin mutants T17M and P347S in transgenic mice and in cell cultures.Proc Natl Acad Sci USA1998 ; 95 : 11933-8.","DOI":"10.1073\/pnas.95.20.11933"},{"key":"R17","doi-asserted-by":"crossref","unstructured":"Pet\u00e4j\u00e4-Repo UE, Hogue M, Bhalla S,et al. Ligands act as pharmacological chaperones and increase the efficiency of \u03b4 opioid receptor maturation.EMBO J2002 ; 21 : 1628-37.","DOI":"10.1093\/emboj\/21.7.1628"},{"key":"R18","doi-asserted-by":"crossref","unstructured":"Janovick JA, Maya-Nunez G, Ulloa-Aguirre A,et al. Increased plasma membrane expression of human follicle-stimulating hormone receptor by a small molecule thienopyr(im)idine.Mol Cell Endocrinol2009 ; 298 : 84-8.","DOI":"10.1016\/j.mce.2008.09.015"},{"key":"R19","doi-asserted-by":"crossref","unstructured":"Riordan JR. The cystic fibrosis transmembrane conductance regulator.Annu Rev Physiol1993 ; 55 : 609-30.","DOI":"10.1146\/annurev.ph.55.030193.003141"},{"key":"R20","doi-asserted-by":"crossref","unstructured":"Kerem B, Rommens JM, Buchanan JA,et al. Identification of the cystic fibrosis gene : genetic analysis.Science1989 ; 245 : 1073-80.","DOI":"10.1126\/science.2570460"},{"key":"R21","doi-asserted-by":"crossref","unstructured":"Germain DP. La maladie de Fabry : de la d\u00e9couverte des lysosomes \u00e0 l\u2019av\u00e8nement de la th\u00e9rapeutique.Med Sci (Paris)2005 ; 21 : 5-7.","DOI":"10.1051\/medsci\/20052111s5"},{"key":"R22","doi-asserted-by":"crossref","unstructured":"Fan JQ, Ishii S, Asano N, Suzuki Y. Accelerated transport and maturation of lysosomal alphagalactosidase A in Fabry lymphoblasts by an enzyme inhibitor.Nat Med1999 ; 5 : 112-5.","DOI":"10.1038\/4801"},{"key":"R23","doi-asserted-by":"crossref","unstructured":"Grabowski GA. Gaucher disease: enzymology, genetics and treatment.Adv Hum Genet1993 ; 21 : 377-441.","DOI":"10.1007\/978-1-4615-3010-7_5"},{"key":"R24","doi-asserted-by":"crossref","unstructured":"Sawkar AR, Cheng WC, Beutler E,et al. Chemical chaperones increase the cellular activity of N370S beta-glucosidase: a therapeutic strategy for Gaucher disease.Proc Natl Acad Sci USA2002 ; 99 : 15428-33.","DOI":"10.1073\/pnas.192582899"},{"key":"R25","doi-asserted-by":"crossref","unstructured":"Mendes HF, Van der Spuy J, Chapple JP, Cheetham ME. Mechanisms of cell death in rhodopsin retinitis pigmentosa : implications for therapy.Trends Mol Med2005 ; 11 : 177-85.","DOI":"10.1016\/j.molmed.2005.02.007"},{"key":"R26","doi-asserted-by":"crossref","unstructured":"Morello JP, Bichet DG. Nephrogenic diabetes insipidus.Annu Rev Physiol2001 ; 63 : 607-30.","DOI":"10.1146\/annurev.physiol.63.1.607"},{"key":"R27","doi-asserted-by":"crossref","unstructured":"Carrell RW, Lomas DA, Sidhar S, Foreman R. alpha1-antitrypsin deficiency: a conformational disease.Chest1996 ; 110 : 243S-47S.","DOI":"10.1378\/chest.110.6_Supplement.243S"},{"key":"R28","doi-asserted-by":"crossref","unstructured":"Foster BA, Coffey HA, Morin MJ, Rastinejad F. Pharmacological rescue of mutant p53 conformation and function.Science1999 ; 286 : 2507-10.","DOI":"10.1126\/science.286.5449.2507"},{"key":"R29","doi-asserted-by":"crossref","unstructured":"Toledo F, Bluteau O, Simeonova I. R\u00e9activation de p53 dans les tumeurs : une strat\u00e9gie antitumorale prometteuse.Med Sci (Paris)2007 ; 23 : 565-7.","DOI":"10.1051\/medsci\/20072367565"},{"key":"R30","doi-asserted-by":"crossref","unstructured":"Lam CW, Xie J, To KF,et al. A frequent activated smoothened mutation in sporadic basal cell carcinomas.Oncogene1999 ; 18 : 833-6.","DOI":"10.1038\/sj.onc.1202360"},{"key":"R31","doi-asserted-by":"crossref","unstructured":"Partridge CJ, Beech DJ, Sivaprasadarao A. Identification and pharmacological correction of a membrane trafficking defect associated with a mutation in the sulfonylurea receptor causing familial hyperinsulinism.J Biol Chem2001 ; 276 : 35947-52.","DOI":"10.1074\/jbc.M104762200"},{"key":"R32","doi-asserted-by":"crossref","unstructured":"Pratt EB, Yan FF, Gay JW,et al. Sulfonylurea receptor 1 mutations that cause opposite insulin secretion defects with chemical chaperone exposure.J Biol Chem2009 ; 284 : 7951-9.","DOI":"10.1074\/jbc.M807012200"},{"key":"R33","doi-asserted-by":"crossref","unstructured":"Kim BE, Smith K, Meagher CK, Petrisd MJ. A conditional mutation affecting localization of the Menkes disease copper ATPase ; suppression by copper supplementation.J Biol Chem2002 ; 277 : 44079-84.","DOI":"10.1074\/jbc.M208737200"},{"key":"R34","doi-asserted-by":"crossref","unstructured":"Liu X, Garriga P, Khorana HG. Structure and function in rhodopsin : correct folding and misfolding in two point mutants in the intradiscal domain of rhodopsin identified in retinitis pigmentosa.Proc Natl Acad Sci USA1996 ; 93 : 4554-9.","DOI":"10.1073\/pnas.93.10.4554"},{"key":"R35","doi-asserted-by":"crossref","unstructured":"Fuchs S, Amiel J, Claudel S,et al. Functional characterization of three mutations of the endothelin B receptor gene in patients with Hirshsprung\u2019s disease: evidence for selective loss of Gi coupling.Mol Med2001 ; 7 : 115-24.","DOI":"10.1007\/BF03401945"},{"key":"R36","doi-asserted-by":"crossref","unstructured":"Lubrano-Berthelier C, Dubern B, Lacorte JM,et al. Melanocortin 4 receptor mutations in a large cohort of severely obese adults : : prevalence, functional classification, genotype-phenotype relationship, and lack of association with binge eating.J Clin EndocrinolMetab2006 ; 91 : 1811-8.","DOI":"10.1210\/jc.2005-1411"},{"key":"R37","doi-asserted-by":"crossref","unstructured":"Clark AJL, Metherell LA, Cheetham ME, Huebner A. Inherited ACTH insensitivity illuminates the mechanisms of ACTH action.Trends Endocrinol Metab2005 ; 16 : 451-7.","DOI":"10.1016\/j.tem.2005.10.006"},{"key":"R38","doi-asserted-by":"crossref","unstructured":"Samson M, Libert F, Doranz BJ,et al. Resistance to HIV-1 infection in caucasian individuals bearing mutant alleles of the CCR-5 chemokine receptor gene.Nature1996 ; 382 : 722-5.","DOI":"10.1038\/382722a0"},{"key":"R39","doi-asserted-by":"crossref","unstructured":"Tfelt-Hansen J, Brown EM. The clacium-sensing receptor in normal physiology and athophysiology: a review.Crit Rev Clin Lab Sci2007 ; 42 : 35-70.","DOI":"10.1080\/10408360590886606"},{"key":"R40","doi-asserted-by":"crossref","unstructured":"Biebermann H, Schoneberg T, Krude H,et al. Mutations of the human thyrotropin receptor gene causing thyroid hypoplasia and persistent congenital hypothyroidism.J Clin Endocrinol Metab1997 ; 82 : 3471-80.","DOI":"10.1210\/jc.82.10.3471"},{"key":"R41","doi-asserted-by":"crossref","unstructured":"Themmen APN, Martens JWM, Brunner HG. Activating and inactivating mutations in LH receptors.Mol Cell Endocrinol1998 ; 145 : 137-42.","DOI":"10.1016\/S0303-7207(98)00180-4"},{"key":"R42","doi-asserted-by":"crossref","unstructured":"Aittom\u00e4ki KJ, Lucena LD, Pakarinen P,et al. Mutation in the folliclestimulating hormone receptor gene causes hereditary hypergonadotropic ovarian failure.Cell1995 ; 82 : 959-68.","DOI":"10.1016\/0092-8674(95)90275-9"},{"key":"R43","doi-asserted-by":"crossref","unstructured":"Beaumont KA, Newton RA, Smit DJ,et al. Altered cell surface expression of human MCR1 variant receptor alleles associated with red hair and skin cancer risk.Hum Mol Genet2005 ; 14 : : 2145-54.","DOI":"10.1093\/hmg\/ddi219"},{"key":"R44","doi-asserted-by":"crossref","unstructured":"Noorwez SM, Malhotra R, McDowell JH,et al. Retinoids assist the cellular folding of the autosomal dominant retinitis pigmentosa opsin mutant P23H.J Biol Chem2004 ; 279 : 16278-84.","DOI":"10.1074\/jbc.M312101200"},{"key":"R45","doi-asserted-by":"crossref","unstructured":"Lees AJ, Hardy J, Revesz T. Parkinson\u2019s disease.Lancet2009 ; 373 : 2055-66.","DOI":"10.1016\/S0140-6736(09)60492-X"},{"key":"R46","doi-asserted-by":"crossref","unstructured":"Sacchetini JC, Kelly JW. Therapeutic strategies for human amyloid diseases.Nat Rev Drug Discov2002 ; 1 : 267-75.","DOI":"10.1038\/nrd769"},{"key":"R47","doi-asserted-by":"crossref","unstructured":"Kobayashi H, Ogawa K, Yao R,et al. Functional rescue of beta-adrenoceptor dimerization and trafficking by pharmacological chaperones.Traffic2009 ; 10 : 1019-33.","DOI":"10.1111\/j.1600-0854.2009.00932.x"},{"key":"R48","doi-asserted-by":"crossref","unstructured":"Stanton BZ, Peng LF. Small molecule modulators of the Sonic Hedgehog signalling pathway.Mol Biosyst2010 ; 6 : 44-54.","DOI":"10.1039\/B910196A"},{"key":"R49","doi-asserted-by":"crossref","unstructured":"Pey AL, Ying M, Cremades N,et al. Identification of pharmacological chaperones as potential therapeutic agents to treat phenylketonuria.J Clin Invest2008 ; 118 : 2858-67.","DOI":"10.1172\/JCI34355"},{"key":"R50","doi-asserted-by":"crossref","unstructured":"Asano N, Ishii S, Kizu H,et al. In vitroinhibition and intracellular enhancement of lysosomal alpha-galactosidase A activity in Fabry lymphoblasts by 1-deoxygalactonojirimycin an dits derivatives.Eur J Biochem2000 ; 267 : 4179-86.","DOI":"10.1046\/j.1432-1327.2000.01457.x"},{"key":"R51","doi-asserted-by":"crossref","unstructured":"Loo TW, Bartlett MC, Wang Y, Clarke DM. Rescue of deltaF508 and other misprocessed CFTR mutants by a novel quinazoline compound.Mol Pharmacol2005 ; 2 : 407-13.","DOI":"10.1021\/mp0500521"},{"key":"R52","doi-asserted-by":"crossref","unstructured":"Korth C, May BC, Cohen FE, Prusiner SB. Acridine and phenothiazine derivatives as pharmacotherapeutics for prion disease.Proc Natl Acad Sci USA2001 ; 98 : 9836-41.","DOI":"10.1073\/pnas.161274798"},{"key":"R53","doi-asserted-by":"crossref","unstructured":"Sigurdsson EM, Permanne B, Soto C,et al. In vivo reversal of amyloid-beta lesions in rat brain.J Neuropathol Exp Neurol2000 ; 59 : 11-7.","DOI":"10.1093\/jnen\/59.1.11"},{"key":"R54","doi-asserted-by":"crossref","unstructured":"Heiser V, Scherzinger E, Boeddrich A,et al. Inhibition of huntingtin fibrillogenesis by specific antibodies and small molecules: implications for huntington\u2019s disease therapy.Proc Natl Acad Sci USA2000 ; 97 : 6739-44.","DOI":"10.1073\/pnas.110138997"}],"container-title":["m\u00e9decine\/sciences"],"original-title":[],"link":[{"URL":"http:\/\/www.medecinesciences.org\/10.1051\/medsci\/2010266-7627\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,6,8]],"date-time":"2019-06-08T18:28:50Z","timestamp":1560018530000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.medecinesciences.org\/10.1051\/medsci\/2010266-7627"}},"subtitle":["Un espoir th\u00e9rapeutique pour les pathologies conformationnelles"],"short-title":[],"issued":{"date-parts":[[2010,6]]},"references-count":54,"journal-issue":{"issue":"6-7"},"alternative-id":["medsci2010266-7p627"],"URL":"https:\/\/doi.org\/10.1051\/medsci\/2010266-7627","relation":{},"ISSN":["0767-0974","1958-5381"],"issn-type":[{"value":"0767-0974","type":"print"},{"value":"1958-5381","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,6]]}}}